This is a study for patients with Non-Hodgkin Lymphoma (NHL) who have relapsed or refractory disease after receiving a CD19+ CAR T cell therapy or are ineligible to receive CD19+ CAR T cell therapy.

The primary purposes of this study are to assess the safety and tolerability of escalating doses of the study drug, MT-601, and to assess the anti-tumor activity or effectiveness of MT-601 against lymphoma. 

MT-601 is considered investigational and is not yet approved by the U.S. Food and Drug Administration (FDA).

In many types of cancer, including NHL, cancer cells may express proteins that are specific to the cancer cell, so they either are not present, or are present in low quantities, on normal human cells. This therapy works by taking some special white blood cells, called T cells, from the blood through a process called apheresis. The cells will be processed in a laboratory, where they will be ‘armed and trained’ to recognize six tumor proteins which may appear on NHL cancer cells. When the T cells are manufactured, they will be called MT-601. Because the blood used to manufacture the study drug comes from each individual and not a donor, MT-601 is called an autologous product.
   
All participants will receive the study drug. Total participation will last up to one year.